In this article, we will take a look at the Top 10 Healthcare Stocks That Could Turn a $1,000 Investment Into Something Bigger.
For much of the past three years, the US healthcare sector has looked like the quiet guest at a very loud Wall Street party. While artificial intelligence stocks, semiconductor names, mega-cap technology companies, and AI infrastructure plays grabbed most of the market’s attention, healthcare stocks were left sitting in the corner, looking unusually cheap, unusually unloved, and, depending on who one asks, unusually interesting.
That may now be the point.
The US healthcare sector has underperformed the broader stock market for three straight years, and the numbers tell the story clearly. Healthcare returned only 0.3% in 2023, followed by 0.9% in 2024, and 12.5% in 2025. Those returns may not sound disastrous in isolation, but compared with the broader market’s stronger gains, they show a sector that has struggled to keep up with investor enthusiasm elsewhere. The weakness has continued into 2026, with the healthcare sector down 1.62% year-to-date, while the S&P 500 has climbed 10.35% over the same period.
For investors searching for the best healthcare stocks to buy, undervalued healthcare stocks, promising healthcare stocks, biotech stocks with upside potential, medical device stocks, pharmaceutical stocks, healthcare value stocks, and defensive stocks with long-term growth potential, this kind of underperformance can be more than just a warning sign. It can also be the start of a setup.
The AI Trade Left Healthcare Behind
The biggest reason healthcare has lagged, according to several market watchers, is not that the sector suddenly lost its importance. People still need medicines, hospitals, diagnostics, medical devices, insurance coverage, drug development, and life-saving treatments regardless of what is trending on Wall Street. The problem is that healthcare has been competing for attention against one of the strongest market stories of the decade: artificial intelligence.
The AI trade has pulled enormous investor interest into technology, semiconductors, cloud computing, data centers, and AI infrastructure stocks. In a market where investors are chasing earnings growth tied to artificial intelligence, defensive sectors like healthcare can look less exciting, even when their fundamentals remain intact. That is exactly the point made by Gareth Powell, Head of Healthcare at Polar Capital, who argued in a May 18 article that investor enthusiasm for artificial intelligence has pulled capital away from defensive corners of the market, including healthcare.
Michael Zinn, Managing Director and Senior Portfolio Manager at UBS, made a similar observation during a June 8 appearance on BNN Bloomberg. Zinn described the market’s recent behavior as a “catch-up trade” tied to rising earnings expectations in AI infrastructure. In simpler terms, investors have been rewarding companies that appear directly connected to the AI boom, while skipping over sectors that look slower, steadier, or more defensive. Healthcare, despite its massive role in the economy, has been one of the sectors left behind.
That is one of the more interesting twists in today’s market. Healthcare is usually seen as a defensive sector, the kind investors often turn to when economic uncertainty rises. But in a market dominated by AI excitement, even defensive quality has not been enough to command investor attention.
Healthcare May Be Turning Into a Value Sector
This is where the story becomes more interesting for long-term investors. Jared Holz, a healthcare strategist at Mizuho Americas, has argued that the healthcare sector has effectively become a value sector. His reasoning is straightforward. After years of investors crowding into technology and AI-related stocks, healthcare valuations have become more reasonable, while expectations for many healthcare companies have fallen.
That combination matters. In the stock market, a sector does not always need perfect conditions to perform well. Sometimes, it only needs expectations to become low enough. When a sector is ignored for years, valuations can compress, investor sentiment can weaken, and even solid companies can trade below what analysts believe they are worth. That appears to be the situation now for several healthcare stocks with strong analyst upside potential.
For investors looking for healthcare stocks with high upside, Wall Street analyst stock picks, top healthcare stocks for 2026, and value stocks in the healthcare sector, the current setup may be worth studying closely. The sector’s underperformance has created a market where some healthcare companies may now offer more attractive risk-reward profiles than they did during periods when investors were more enthusiastic.
Healthcare has always been a broad sector. It includes pharmaceutical companies, biotechnology firms, hospital operators, managed care companies, diagnostics businesses, medical technology companies, life sciences tools providers, and healthcare services firms. Some of these companies are defensive and cash-generating. Others are higher-risk, catalyst-driven names tied to drug approvals, clinical trial results, regulatory decisions, and product launches. That mix gives investors several ways to approach the sector, depending on their risk appetite.
Why Wall Street Is Starting to Look Again
The renewed interest in healthcare stocks is not just about cheap valuations. It is also about history. SentimenTrader’s Jay Kaeppel has advised investors to put healthcare back on the radar, noting that the sector has rarely performed this poorly relative to the S&P 500. His view suggests that healthcare’s weak year-to-date showing may not be a reason to ignore the sector, but rather a reason to examine whether a rebound is becoming more likely.
That does not mean every healthcare stock is a bargain. It also does not mean investors should blindly buy the sector just because it has lagged. Healthcare investing can be complicated. Drugmakers face patent cliffs. Biotech companies face clinical trial risk. Medical device companies can be affected by hospital spending cycles. Managed care companies can be pressured by regulation, reimbursement trends, and utilization costs. Even large healthcare companies can struggle when policy uncertainty rises or growth expectations fall.
Still, the sector’s current position is hard to dismiss. Healthcare stocks have underperformed for several years, valuations appear more reasonable, and analyst price targets suggest that select names may have significant upside from current levels. For investors who believe the AI trade has become crowded, healthcare may offer a different kind of opportunity: less flashy, less crowded, but potentially more attractively priced.
There is also a useful bit of market trivia here. Healthcare is one of the few sectors that can be both defensive and innovative at the same time. A pharmaceutical company may generate steady revenue from established medicines while also developing next-generation therapies. A medical device company may serve everyday hospital demand while also introducing advanced technologies that improve surgery, imaging, or patient monitoring. A biotech company may look speculative today but become highly valuable if a major treatment succeeds. That is why healthcare often attracts both conservative investors and aggressive growth investors, even though they may be looking at very different types of companies.
The Sector Nobody Wanted May Now Be the One to Watch
The irony is that healthcare’s weakness may be exactly what makes it interesting now. Wall Street has spent years focusing on AI stocks, semiconductor stocks, mega-cap technology names, and companies tied to the digital infrastructure boom. Meanwhile, many healthcare stocks have been quietly reset. Expectations have moved lower. Valuations have become more reasonable. Analysts are starting to identify names with large upside potential. And the sector’s poor relative performance has become difficult to ignore.
For investors searching Google for the most promising healthcare stocks, best healthcare stocks according to Wall Street analysts, healthcare stocks with upside potential, undervalued biotech stocks, top pharmaceutical stocks, and healthcare stocks to buy now, the current market backdrop creates an important question: has healthcare been forgotten for too long?
That is the central idea behind this article. The healthcare sector is not suddenly risk-free, and not every beaten-down stock deserves a second look. But after three consecutive years of lagging the broader market and another weak start in 2026, the sector now sits in a position where Wall Street analysts see meaningful upside in select names. In a market where many investors are still chasing AI-linked winners, healthcare may offer something different: a mix of value, defensiveness, innovation, and recovery potential.
CHECK THIS OUT: Top 10 Small-Cap Biotech Stocks With Billion-Dollar Upside Potential and Top 10 Biotech Stocks That Could Climb as Much as 100%.
Our Methodology
In order to come up with our list of the top 10 healthcare stocks that could turn a $1,000 investment into something bigger, we used the Finviz stock screener to identify US-listed healthcare stocks with average analyst price targets at least 50% above their current share prices as of June 16, 2026, reviewed hedge fund ownership in Q1 2026 for added institutional context, and ranked the final list in ascending order of implied upside potential.
Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger
10. BeOne Medicines AG (NASDAQ:ONC)
Stock Upside: 55.26%
Market Capitalization: $32.74 billion
BeOne Medicines AG (NASDAQ:ONC) opens this ranking of the most promising healthcare stocks according to Wall Street analysts, and it does so with the kind of cancer-drug pipeline story that tends to make biotech investors lean closer to the screen. Trading at $270.15, with the stock up 2.84%, BeOne Medicines AG (NASDAQ) carries a market capitalization of $32.74 billion and an estimated stock upside of 55.26%, making it one of the healthcare stocks with strong analyst upside potential. For investors searching for biotech stocks to buy, cancer treatment stocks, oncology stocks, pharmaceutical stocks with upside, and Wall Street healthcare stock picks, BeOne is not just another clinical-stage name trying to sell a dream. It is a commercial-stage biopharmaceutical company with a deep oncology focus, a growing global footprint, and several pipeline assets aimed at areas where patients still badly need better options.
The latest attention around BeOne Medicines AG (NASDAQ) came after Citizens kept its Market Outperform rating and $396 price target on the stock on June 3. That call followed BeOne’s presentation of tumor clinical data at the American Society of Clinical Oncology, or ASCO 2026, one of the most closely watched cancer research events in the world. For context, ASCO is not just another medical conference. In oncology investing, ASCO can move sentiment because it is where investors, physicians, drug developers, and analysts study whether a company’s cancer pipeline is gaining real scientific traction. A promising ASCO update can push a biotech stock higher, while disappointing data can quickly cool investor enthusiasm. In BeOne’s case, Citizens appeared encouraged by the strength and breadth of the company’s tumor data, especially because the results touched several difficult cancer categories.
Citizens highlighted three pipeline drugs in particular. The first was BGB-43395, which BeOne is testing in HR-positive, HER2-negative metastatic breast cancer. That form of breast cancer is common, but it is also difficult because patients can eventually develop resistance to existing therapies. The second was BG-C9074, an antibody-drug conjugate being evaluated for ovarian cancer maintenance. Antibody-drug conjugates, often called ADCs, have become one of the most exciting areas in oncology because they are designed to deliver cancer-killing treatment more directly to tumor cells, potentially improving efficacy while limiting some broader toxicities. The third was BGB-B2033, a bispecific antibody being tested in liver cancer, another disease area where treatment choices remain limited and outcomes can still be poor.
What makes BeOne Medicines AG (NASDAQ) especially interesting as one of the top healthcare stocks according to analysts is that Citizens believes these programs are targeting patient groups where the current standard of care still has major gaps. Some existing treatments can be too toxic. Others may eventually stop working because of resistance. In some areas, truly effective treatment options remain limited. That matters because biotech stock upside often depends not only on whether a company can produce good clinical data, but also on whether that data speaks to a meaningful unmet medical need. In BeOne’s case, the analyst view is that the company’s tumor pipeline is moving beyond theory and into a more serious phase of execution.
Citizens said it arrived at its $396 price target using a discounted earnings and revenue multiple analysis, which suggests that the firm is looking not only at future scientific promise but also at the financial structure behind the business. That is important because ambitious oncology pipelines can be expensive. BeOne is trying to develop multiple novel cancer therapies, and that usually requires heavy investment in clinical trials, regulatory work, manufacturing, and commercialization. The firm pointed to BeOne’s $4.85 billion cash position, its stronger cash position relative to debt, and gross profit margins of 88% as reasons to believe the company has the balance sheet strength to support its pipeline ambitions. In simple terms, BeOne does not appear to be running this oncology strategy on fumes.
BeOne Medicines AG (NASDAQ) is a commercial-stage biopharmaceutical company focused on developing novel therapies for cancer, including candidates for solid tumors and hematologic malignancies. For investors looking for the best healthcare stocks to buy now, promising biotech stocks, cancer therapy stocks, and healthcare stocks with high upside potential, BeOne stands out because it combines commercial maturity with pipeline optionality. The stock is not cheap in absolute dollar terms, but analysts still see meaningful upside from current levels. That makes it a name to watch in the healthcare sector, especially at a time when investors are again asking whether undervalued healthcare stocks and biotech stocks may finally get more attention after years of market leadership from artificial intelligence and mega-cap technology.
Click next to see the following stock...
